Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tokai Tokyo Research Forecasts Continued Growth for Matsumotokiyoshi
February 18, 2002
- Requirements for Biologic Products, Antibiotics Revised
February 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 18, 2002
- 30% Hike of Copayment Agreed
February 18, 2002
- Korosho to Review Drug Reevaluation System
February 18, 2002
- WORLD NEWS IN BIREF
February 18, 2002
- Mochida to Expand Its Business Fields
February 11, 2002
- LDP to Review Safety Measures against Medical Devices
February 11, 2002
- Sankyo to Beef Up Business Development in China
February 11, 2002
- Shimadzu: Multi-channel Oxygen Monitors
February 11, 2002
- WEBSITE NEWS
February 11, 2002
- Brand Generic Business Likely to Be Brisk
February 11, 2002
- BUSINESS NEWS IN BRIEF
February 11, 2002
- Wholesalers Concerned over Effects of Medical Fee Cut: JPPA
February 11, 2002
- Recovery of Business Performance Stressed by President: Tsumura
February 11, 2002
- Japanese Society of Process Chemistry Created
February 11, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
February 11, 2002
- Korosho Clarifies Marketing Approval System
February 11, 2002
- Good Results Obtained in Vascular Dementia PIII Study on Aricept: Int'l Congress
February 11, 2002
- Korosho Proposes to Reduce Re-pricing Ceiling from 25% to 15%
February 11, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…